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1RANSPLANTATION 
Abstract from 1970 
THOMAS E. STARZL. MD, PhD. FACS 
Preservation 
Widespread and efficient use of organ homografts 
will not be possible without major developments in 
organ preservation that will allow banking for weeks 
or months. Ethacrynic acid and furosemide have a 
protective effect on rat kidneys if the drugs were ad-
ministered at the beginning of the interval of vascular 
cross clamping. Canine kidney allografts were kept 
viable for 24 hours being perfused at low flow rates 
with a fluorocarbon in a cold salt solution emulsion. 
Surface cooling alone kept kidney auto grafts in good 
condition for 8 hours. 
Excised canine hearts began. to decay after 2 
hours, whether left alone or perfused with oxygen-
ated blood. In skin, there was no loss of antigenicity 
with freezing alone, but after freezing and lyophiliza-
tion, histocompatability antigens could no longer be 
identified nor could second set reactions be induced. 
The clinical implication is that this kind of biologic 
dressing can be used without danger of recipient sen-
sitization. 
Diagnoses of Rejection 
Urinary and serum concentrations oflactic dehy-
drogenase and alpha hydroxybutyric dehydrogenase 
were measured as indices of either physical or immu-
nologic injury to renal homografts or autografts. 
There were elevations in both, but organ specificity 
was greater with alpha hydroxybutyric dehydroge-
nase. In cardiac transplantation, studies showed that 
the best diagnostic indicators of rejection are clinical 
observation and electrocardiography. Sepsis of the 
homograft in liver transplantation should not arbi-
trarily be ascribed to rejection, because hepatic ab-
scesses and cholangitis were seen in experiments in 
the absence of an immunologic barrier. A decline in 
blood flow is a characteristic feature of all rejecting 
homografts. 
Humoral Antibodies and Rejection 
The classic view of rejection has been that de-
structive agents are mononuclear cells. but there is 
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growing belief that circulating immunoglobulins 
play an important role in rejection. Sera from renal 
homograft recipients without overt rejection did not 
develop easily detectable antibodies, but in patients 
with clinically diagnosed rejection, cytotoxic anti-
bodies were regularly found. When cytotoxic anti-
bodies are present in a patient before transplantation, 
there is increased risk that the homograft may un-
dergo immediate destruction. 
Antilymphocyte Serum 
Of all the immunosuppressive agents, heterolo-
gous antilymphocyte serum received the most atten-
tion. One study demonstrated that antisera could be 
raised against specific populations of lymphocytes. 
To date, there is no totally reliable in vitro test for 
assessing the immunosuppressive potency of anti-
lymphocyte sera. The most specific risk of chronic 
therapy with heterologous serum or globulin is sen-
sitization to the injected foreign protein. One study 
showedrhat tolerance to horse globulin could be pro-
duced with a course of intravenous antilymphocyte 
globulin, but other researchers warned that repeated 
infusion of high potency antilymphocyte serum 
causes local thrombosis and vasculitis. 
Other Immunosuppressive Measures 
In both humans and calves, mechanicallympho-
cyte depletion by thoracic duct drainage caused early 
rejection that was mild and late. Skin graft survival 
was prolonged using local homograft irradiation. 
Thiomycetin (thiamphenicol) significantly slowed 
rejection of canine renal homografts. Canine kidney 
recipients lived longer when treated with a protocol 
that substituted medroxyprogesterone for pred-
nisone and also included azathioprine. Clinical trials 
with medroxyprogesterone substituting for pred-
nisone are awaited with interest because of the exces-
sively high morbidity rate after high dose prednisone 
therapy in kidney recipients. A study in rabbits 
showed that steroids caused increases in serum lipids, 
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forming fat emboli that passed to terminal arterioles 
of bone and caused osteoporosis and osteonecrosis. 
Graft Acceptance 
One study showed a relation between sensitiza-
tion and tolerance that depended on the dose of sen-
sitizing antigen and the strength of the histocompat-
ability barrier. Survival was prolonged in rats 
receiving kidney homografts when they were condi-
tioned before the operation by intravenous adminis-
tration of donor genotype spleen cells and injection 
of specific antidonor serum, suggesting that both tol-
erance and enhancement are factors in graft protec-
tion. It was reported that Kupffer cells of hepatic 
transplants became of host origin at all times after 3 
months. 
Graft Function 
In dogs, reimplanted forelimbs almost never 
functioned normally, but gave auxiliary support. Per-
fused porcine spleens synthesized anti hemophiliac 
globulin well enough to support the concept of 
splenic transplantation to treat hemophilia. Research 
reaffirmed the desirability of perfusing the portal sys-
tem of liver homografts with venous blood from the 
splanchnic bed, but even when perfused, atrophy was 
usually observed if the hepatic transplants were used 
as auxiliary organs in dogs. It was reported that in 
liver transplantation, the homograft can synthesize 
protein of a new type, and that new gamma G glob-
ulin phenotypes were conferred on human recipients 
of orthotopic livers. In pulmonary transplantation, 
auto grafts had regeneration of efferent autonomic 
nerves by 2 to 6 months, but not of afferent auto-
nomIC nerves. 
Heterotransplantation 
Treatment with antilymphocyte serum signifi-
cantly prolonged graft survival in skin transplanta-
tion from rats or hamsters to mice. When porcine 
kidneys were transplanted to goats, organ survival 
was one day in untreated recipients, but it increased 
to 14 days when antilymphocyte globulin and cyto-
sine arabinoside were given. Pretreating rabbit kid-
neys with a collagen emulsion prepared from calf 
skin slowed the rejection process by 10 times in trans-
plantation to dogs. 
Surgical Technique 
In the Shumway-Lower technique for orthotopic 
cardiac transplantation in dogs, using a Teflon cou-
pler to reconnect the aorta and pulmonary artery 
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lowered ischemia time and eliminated hemorrhage 
encountered in suturing the canine aorta. 
Clinical Notes 
The longest followup period is now 5 months for 
patients still living after combined pancreatic and 
renal transplant. Six patients have survived a year or 
more after liver transplant, and it appears the prime 
indication for liver transplantation in the future will 
be for benign diseases, such as biliary atresia and 
cirrhosis. Between six and ten patients have lived for 
a year or more after cardiac transplantation, the long-
est survival period being 17 months. Whats New in 
Surgery, "Transplantation," Surg Gynecol Obstet, 
1970, 130:316-321. 
Author's Retrospective 
THOMAS E. STARZL, MD, PhD, FACS 
University of Pittsburgh School of Medicine. 
Pittsburgh Transplantation Institute, Pittsburgh. PA 
My "What's New" comments in the 1970 issue of 
Surgery, Gynecology, and Obstetrics (now Journal of the 
American Col/ege of Surgeons) reflected the recent 
birth of this new specialty. Essentially all of the cita-
tions were from papers presented at the 1969 Surgi-
cal Forum, where fresh ideas are presented by young 
mvesngators. 
The center pole of transplantation, then as now, 
is immunosuppression, with supporting struts of re-
jection, mechanisms of graft acceptance (and toler-
ance), preservation, tissue matching, and physiologic 
implications of allogeneic organ function. Major ad-
vances in each of these areas were made between 
1959 and 1968, allowing the movement of organ 
transplantation to the clinics. 
These areas all were subjects of reports at the 
Surgical Forum in the consolidation year of 1969. 
Organ preservation, the "orphan" of transplantation, 
was given special attention in my reporr, which be-
moaned the fact that the only substantive progress 
had been with short-term "static" conservation based 
on hypothermia rather than technologies that would 
permit organ banking for weeks or months. Al-
though banking at a praccicallevel is no closer today 
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than it was 28 years ago, the sophisticated technology 
is there and may be picked up again. In the mean-
while, "short term" became "medium term" stacic 
preservation using the CollinsfTerasaki (1969) and 
University of Wisconsin solutions (1987). Ironically, 
the latter accomplishment by the late Folkert Belzer 
rendered obsolete the same Belzer's asanguineous 
perfusion technique (1968). Compared with other 
progress in transplantation, preservation remains an 
orphan. 
By 1969, the concern of the 1950s and early 
1960s about the adverse effects of organ denervation 
had been allayed. It also was generally conceded that 
normal physiologic processes were so closely shared 
by members of the same species that serious meta-
bolic handicaps would not be imposed on recipients 
unless the donor (particularly of a liver) had undetec-
ted metabolic abnormalities. An important ripple ef-
fect of hepatic transplantation was the discovery 
(1960-1967) that splanchnic venous blood con-
tained specific liver-supporting ingredients that pre-
vented liver atrophy and were required for optimal 
hepatic regeneration. Although this was still contro-
versial in 1969, the demonstration in transplant-
derived models that insulin is a major liver growth 
factor (1973-1976) was the beginning of the special 
discipline of hepatotrophic (growth factor) physiol-
ogy. This discipline continues to burgeon today and 
influences decisions in both transplantation and 
nontransplant surgery. 
Although it is worth reflecting on what has hap-
pened in these broad areas in the nearly 3 decades 
since the 1969 Surgical Forum, the greatest changes 
have been in applied immunology. Without these, 
clinical transplantation would have atrophied from 
the state to which it had dramatically risen from zero, 
only to become mired at an unsatisfactory plateau by 
the end of the 1960s. All of the major organs had 
been successfully transplanted, but none reliably 
enough ro be a legitimate clinical service. The im-
pending ordeal of brownian movement would last 
for a decade. 
IMMUNE SUPPRESSION 
Less than 6 years after the systematic use of azathio-
prine and prednisone was first reported, the search 
was already on in 1969 for a replacement for the 
relatively weak and myelotoxic azathioprine (eg, 
thiampherical. an analogue of chloromycetin). It 
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would be 10 years before the arrival of cyclospor-
ine (Sir Roy Calne, 1978), followed by tacrolimus 
(1989), which also required use with dose-
maneuverable adrenal cortical steroids. Studies of a 
third (adjunct) agent, polyclonal antilymphocyte 
globulin, dominated sessions at the 1969 Surgical 
Forum. 
Although antilymphocyte globulin had been 
used clinically since 1966 and was credited with ex-
tension of transplantation from the kidney to extra-
renal organs (eg, liver, heart), numerous controversial 
questions remained: its refinement from animal se-
rum, the appropriate potency assay, toxicity (includ-
ing oncogenicity), and optimal treatment schedul-
ing. Evidence was presented at the 1969 meeting that 
lymphocyte subpopulations could be deleted or 
"blindfolded" according to the choice of lymphoid 
cells used to immunize the animal serum donor. This 
possibility was fully realized in the 1980s and 1990s 
with the engineering with hybridomas of monoclo-
nal antilymphoid antibodies and, more recently, an-
tibodies directed with laser precision to cell receptors 
and other increasingly discrete targets. 
GRAFf ACCEPTANCE VERSUS REJECTION 
Until 1969, the collective immunologist's view of 
rejection, not shared by many experienced transplant 
clinicians, was that rejection was a pure expression of 
cellular immunity. Yet, between 1965 and 1969, 
antibody-associated hyperacute rejection had been 
identified (Paul Terasaki), and Yoji Iwasaki and 
David Talmage had demonstrated (with an antiglob-
ulin consumption test) seemingly harmless antibod-
ies after virtually every successful kidney transplanta-
tion. Hypotheses were being formulated that 
included a role for "enhancing antibodies" to explain 
organ allograft acceptance by mechanisms other than 
the donor leukocyte chimerism that Billingham, 
Brent, and Medawar had found to be a necessary 
condition for acquired neonatal immunologic 
tolerance. 
The chimerism-exclusionary theories were un-
challenged for 30 years, beginning in 1962. This ef-
fectively disconnected the development of organ 
transplant surgery from the scientific base enjoyed by 
bone marrow rransplantation, which ironically was 
not done successfully until 1968, 9 years after Joseph 
Murray's first successful kidney allotransplantation. 
A golden opportunity to avert the epistemologic col-
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lapse was missed at the 1969 Surgical Forum, when 
the full significance was not appreciated of the most 
important paper of the Congress, given by Kashi-
wagi. In the first longterm surviving female recipi-
ents of male livers, Kashiwagi reported the observa-
tion by his collaborator, K. A. Porter (London), that 
the nonparenchymalleukocyte population of human 
hepatic allografts had invariably been replaced by fe-
male recipient cells of the same lineages, converting 
the liver to a male!female composite. The products of 
hepatocyte synthesis changed permanently to donor 
phenotypes, allowing assurance that hepatic-based 
inborn errors of metabolism would be cured by liver 
replacement. Paradoxically, new gamma-globulin 
phenotypes of donor origin also were conferred upon 
these recipients. Although this meant that the re-
placed donor leukocytes had migrated and engrafted 
peripherally, the concept was so alien in 1969 and for 
years afterward that no one thought to look periph-
erally for the donor cells. When they were found in 
1992 in kidney and liver recipients 10-30 years after 
transplantation, it was realized that donor leukocyte 
migration and chimerism were fundamental to the 
acceptance of all varieties of organ allografts. 
The story was not completed until 1997, when 
transplantation immunity and infectious immunity 
were reconciled by Starzl and Zinkernagel.! It can 
now be stated with conviction that acquired toler-
ance to noncytopathic microorganisms and accep-
tance of allografts are variations on the same theme 
and are dependent on the same mechanisms. The 
donor-specific nonreacrivity is explained primarily 
by donor leukocyte-driven clonal exhaustion! 
deletion (activation-associated tolerance). This pro-
cess and its subsidiary mechanism of "immune indif-
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ference" are governed by antigen migration and 
localization, as opposed to the antigen per se. 
In addition, most of the enigmas that made or-
gan transplantation appear to follow different rules 
than bone marrow transplantation were resolved. 
With the hematolymphopoietic cytoablation (with 
irradiation or cytotoxic drugs) used to precondition 
bone marrow transplant patients, the recipients were 
made vulnerable to a one-way graft-versus-host reac-
tion unless the donor was HLA matched. In contrast, 
the "nullification" occurring after organ transplantation 
with a double immune reaction (graft-versus-host and 
host-versus-graft [rejection]) allowed hepatic, hearr-
lung, intestinal, and abdominal multivisceral grafts to 
be transplanted to nonconditioned recipients with im-
purity, and with "blindfolding" of the HLA-matching 
effect. The surprisingly poor prognostic discrimination 
of HLA matching in kidney transplantation could be 
discussed without rhetoric for the first time, allowing a 
consensus development to begin for resolving the 30-
year controversy about the value of HLA matching, 
which was just surfacing in 1969. 
Without the insights into mechanisms of graft 
acceptance that have evolved recently, it is very difficult 
to envision moving on to the successful use of xeno-
grafts from phylogenetically close, much less more dis-
tant (discordant), species. Having moved inside a seam-
less conceptual world, it has been easier to look out than 
it was trying to see in from the murky outside.2 
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